Musculoskeletal Cell Reprogramming via Non-Viral Transcription Factors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for musculoskeletal diseases, such as low back pain, are highly invasive and fail to address the underlying pathology, leading to further disease progression and pain, while existing methods like engineered constructs, cell therapies, drug delivery, and gene editing pose biocompatibility, mechanical integrity, and regulatory challenges.
Innovation Solution
Non-viral delivery of polynucleotides encoding transcription factors, such as HIF-1α, FOX, SOX, and Mohawk families, or extracellular vesicles containing these factors, to reprogram diseased musculoskeletal cells like nucleus pulposus, annulus fibrosis, and cartilage endplate cells into healthy cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral reprogramming or gene editing is used, then reprogramming efficiency is improved, but immunogenic and mutagenic effects worsen
Solution Approach 1:
The patent uses non-viral delivery systems (lipid nanoparticles, electroporation, microinjection) as intermediary methods to deliver transcription factor genes into cells without using viral vectors. This intermediary approach achieves gene delivery while avoiding the immunogenic and mutagenic risks associated with viral integration into the host genome.
Solution Approach 2:
The patent employs transient, non-integrating delivery methods that do not require permanent genetic modification. The transcription factor genes are delivered temporarily to reprogram cells without integrating into the host genome, avoiding long-term mutagenic effects while achieving the desired reprogramming outcome.
2Strength
If engineered constructs are used for replacement, then mechanical integrity is improved, but biocompatibility worsens
Solution Approach 1:
The patent activates the body's own cells to regenerate healthy tissue by delivering transcription factors that reprogram diseased cells back to their healthy state. This self-service approach uses the patient's own biological systems to produce biocompatible tissue rather than introducing foreign engineered constructs that may cause immune rejection.
Solution Approach 2:
The patent changes the functional parameters of existing cells through transcription factor delivery, transforming diseased cells back into healthy cells. This parameter change approach maintains the biocompatibility of native tissue while restoring its functional properties, avoiding the biocompatibility issues of foreign engineered materials.
3Duration of action of stationary object
If cell therapies are used, then long-term cell viability is improved, but the harsh avascular environment worsens cell survival
Solution Approach 1:
The patent enables cells to reprogram themselves locally within the avascular environment by delivering transcription factors directly to the target cells. This self-service mechanism allows cells to adapt and survive in the harsh avascular conditions of tissues like the intervertebral disc without requiring external support or vascularization.
Solution Approach 2:
The patent uses non-viral delivery vectors as intermediaries to transport transcription factors into cells in the avascular environment. These intermediaries protect the genetic material during delivery and enable successful reprogramming despite the challenging lack of blood supply and nutrient delivery to the target tissue.
Data Source
AI summary
Disclosed herein are compositions and methods for reprogramming diseased musculoskeletal cells both in vitro and in vivo. In some embodiments, the disclosed method involves non-virally delivering intracellularly into the diseased musculoskeletal cells a polynucleotide comprising one or more nucleic acid sequences encoding one or more of the disclosed transcription factors.